Ultragenyx Pharmaceutical (RARE) Financials

$37.35 +0.69 (+1.88%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$37.36 +0.02 (+0.04%)

As of 07:00 AM Eastern

Annual Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-146	-246	-302	-198	-403	-187	-454	-707	-607	-569
Consolidated Net Income / (Loss)	-146	-246	-302	-198	-403	-187	-454	-707	-607	-569
Net Income / (Loss) Continuing Operations	-146	-246	-302	-198	-403	-187	-454	-707	-607	-569
Total Pre-Tax Income	-146	-246	-318	-197	-399	-185	-453	-702	-608	-568
Total Operating Income	-148	-248	-329	-371	-424	-330	-382	-649	-569	-536
Total Gross Profit	0.00	0.13	2.61	50	95	265	335	335	389	484
Total Revenue	0.00	0.13	2.61	51	104	271	351	363	434	560
Operating Revenue	0.00	0.13	2.61	51	104	271	351	363	434	560
Total Cost of Revenue	0.00	0.00	0.00	1.15	9.01	6.13	16	28	45	77
Operating Cost of Revenue	0.00	0.00	0.00	1.15	9.01	6.13	16	28	45	77
Total Operating Expenses	148	248	332	422	519	595	717	984	958	1,019
Selling, General & Admin Expense	33	65	100	128	162	183	220	278	310	322
Research & Development Expense	115	183	232	294	357	412	497	706	648	698
Total Other Income / (Expense), net	2.12	2.17	11	174	25	145	-71	-53	-39	-32
Interest Expense	-	-	0.00	0.00	1.14	33	29	43	66	63
Interest & Investment Income	2.32	3.79	4.07	9.54	27	177	-40	-8.23	27	35
Other Income / (Expense), net	-0.20	-1.62	6.53	165	-0.79	0.61	-1.69	-1.57	-0.34	-3.96
Income Tax Expense	0.00	0.04	-16	0.51	3.28	1.21	1.04	5.70	-1.83	1.60
Basic Earnings per Share	($3.96)	($6.21)	($7.12)	($3.97)	($7.12)	($3.07)	($6.70)	($10.12)	($8.25)	($6.29)
Weighted Average Basic Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.80M	69.91M	73.54M	90.54M
Diluted Earnings per Share	($3.96)	($6.21)	($7.12)	($3.97)	($7.12)	($3.07)	($6.70)	($10.12)	($8.25)	($6.29)
Weighted Average Diluted Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.80M	69.91M	73.54M	90.54M
Weighted Average Basic & Diluted Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.80M	70.22M	82.34M	92.50M

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-245	-152	-164	-160	-160	-123	-171	-132	-134	-133	-151
Consolidated Net Income / (Loss)	-245	-152	-164	-160	-160	-123	-171	-132	-134	-133	-151
Net Income / (Loss) Continuing Operations	-245	-152	-164	-160	-160	-123	-171	-132	-134	-133	-151
Total Pre-Tax Income	-239	-153	-163	-159	-159	-127	-170	-131	-133	-133	-150
Total Operating Income	-225	-146	-154	-148	-145	-122	-165	-116	-132	-122	-143
Total Gross Profit	82	98	88	98	87	115	91	126	118	148	111
Total Revenue	91	103	100	108	98	127	109	147	139	165	139
Operating Revenue	91	103	100	108	98	127	109	147	139	165	139
Total Cost of Revenue	8.63	5.32	12	9.91	11	12	18	21	21	17	29
Operating Cost of Revenue	8.63	5.32	12	9.91	11	12	18	21	21	17	29
Total Operating Expenses	307	244	242	246	232	237	257	242	250	270	254
Selling, General & Admin Expense	70	73	77	81	75	77	78	81	80	82	88
Research & Development Expense	237	171	166	165	157	161	178	162	170	188	166
Total Other Income / (Expense), net	-14	-7.66	-9.37	-11	-14	-4.84	-4.88	-14	-1.23	-11	-6.83
Interest Expense	15	16	16	15	18	17	16	16	16	16	14
Interest & Investment Income	1.86	8.04	5.96	6.23	4.46	10	13	3.41	11	8.00	6.67
Other Income / (Expense), net	-1.11	0.18	0.31	-1.99	-0.70	2.04	-1.61	-1.83	3.08	-3.61	0.84
Income Tax Expense	6.29	-1.45	0.50	0.73	0.65	-3.70	0.46	0.86	0.30	-0.02	1.31
Basic Earnings per Share	($3.50)	($2.17)	($2.33)	($2.25)	($2.23)	($1.44)	($2.03)	($1.52)	($1.40)	($1.34)	($1.57)
Weighted Average Basic Shares Outstanding	70.05M	69.91M	70.37M	70.90M	71.66M	73.54M	84.29M	86.58M	95.49M	90.54M	96.29M
Diluted Earnings per Share	($3.50)	($2.17)	($2.33)	($2.25)	($2.23)	($1.44)	($2.03)	($1.52)	($1.40)	($1.34)	($1.57)
Weighted Average Diluted Shares Outstanding	70.05M	69.91M	70.37M	70.90M	71.66M	73.54M	84.29M	86.58M	95.49M	90.54M	96.29M
Weighted Average Basic & Diluted Shares Outstanding	70.11M	70.22M	70.81M	71.49M	82.11M	82.34M	83.13M	92.17M	92.34M	92.50M	94.54M

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	69	69	-62	13	321	290	-417	-172	82	-35
Net Cash From Operating Activities	-106	-161	-254	-291	-345	-132	-339	-380	-475	-414
Net Cash From Continuing Operating Activities	-106	-161	-254	-291	-345	-132	-339	-384	-475	-414
Net Income / (Loss) Continuing Operations	-146	-246	-302	-198	-403	-187	-454	-707	-607	-569
Consolidated Net Income / (Loss)	-146	-246	-302	-198	-403	-187	-454	-707	-607	-569
Depreciation Expense	1.38	3.42	5.83	20	8.54	12	13	18	26	36
Amortization Expense	5.64	4.84	1.71	-2.64	-6.21	0.85	6.61	2.70	-13	-13
Non-Cash Adjustments To Reconcile Net Income	25	50	61	-85	72	3.14	101	246	134	118
Changes in Operating Assets and Liabilities, net	7.74	26	-20	-25	-17	38	-5.74	56	-15	14
Net Cash From Investing Activities	-292	91	55	-33	-13	-179	-195	-292	168	-18
Net Cash From Continuing Investing Activities	-292	91	55	-33	-13	-179	-195	-292	168	-18
Purchase of Property, Plant & Equipment	-4.96	-10	-2.79	-4.08	-25	-44	-73	-116	-44	-7.49
Acquisitions	0.00	0.00	-143	0.00	-14	-37	0.00	-105	-2.50	-13
Purchase of Investments	-624	-442	-230	-510	-693	-813	-1,012	-615	-526	-409
Sale and/or Maturity of Investments	338	544	432	310	719	721	891	545	746	413
Other Investing Activities, net	-1.54	-	-	0.00	0.00	-5.56	-0.94	-0.84	-5.05	-2.44
Net Cash From Financing Activities	468	139	136	337	679	600	119	501	388	399
Net Cash From Continuing Financing Activities	468	139	136	337	679	600	119	501	388	399
Repayment of Debt	0.00	0.00	-4.94	0.00	0.00	-0.24	-0.49	-0.56	-0.03	0.00
Issuance of Common Equity	468	139	141	337	365	601	119	11	388	399
Other Financing Activities, net	-	-	0.00	0.00	314	0.00	0.00	491	0.00	0.00
Effect of Exchange Rate Changes	0.00	-0.07	0.53	-	-0.17	1.12	-1.19	-1.08	0.46	-2.53

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	234	-259	-46	16	-29	141	-97	368	-330	24	-45
Net Cash From Operating Activities	-95	-90	-157	-116	-118	-84	-191	-77	-67	-80	-166
Net Cash From Continuing Operating Activities	-95	-94	-157	-116	-118	-84	-191	-77	-67	-80	-166
Net Income / (Loss) Continuing Operations	-245	-152	-164	-160	-160	-123	-171	-132	-134	-133	-151
Consolidated Net Income / (Loss)	-245	-152	-164	-160	-160	-123	-171	-132	-134	-133	-151
Depreciation Expense	4.69	4.96	5.24	5.36	7.19	8.22	8.85	8.86	8.76	9.08	8.99
Amortization Expense	0.97	-1.65	-2.99	-3.22	-2.68	-3.95	-3.76	-2.95	-3.12	-2.81	-1.73
Non-Cash Adjustments To Reconcile Net Income	122	36	43	34	34	22	31	32	30	25	34
Changes in Operating Assets and Liabilities, net	22	18	-38	7.16	2.80	13	-56	16	31	23	-57
Net Cash From Investing Activities	-162	-172	111	99	64	-107	94	61	-276	103	120
Net Cash From Continuing Investing Activities	-162	-172	111	99	64	-107	94	61	-276	103	120
Purchase of Property, Plant & Equipment	-26	-27	-25	-14	-3.70	-1.60	-3.21	-2.01	-1.62	-0.65	-1.32
Acquisitions	-75	0.37	0.00	-2.50	-	-	-10	-2.50	-	-	-15
Purchase of Investments	-211	-199	-62	-103	-139	-222	-22	-3.37	-367	-16	0.00
Sale and/or Maturity of Investments	151	54	202	220	208	116	132	68	94	119	137
Other Investing Activities, net	-0.18	-0.60	-3.95	-0.40	-0.43	-0.27	-2.07	-0.04	-0.20	-0.13	-0.78
Net Cash From Financing Activities	492	1.88	-0.72	33	25	331	-0.06	385	11	3.19	0.16
Net Cash From Continuing Financing Activities	492	1.88	-0.72	33	25	331	-0.06	385	11	3.19	0.16
Repayment of Debt	-0.15	-0.12	0.03	-0.06	-	-	0.00	-	-	-	0.00
Issuance of Common Equity	1.07	2.00	-0.75	33	25	331	-0.06	385	11	3.19	0.16
Effect of Exchange Rate Changes	-1.08	1.35	0.21	-0.14	-0.72	1.10	-0.68	-0.65	1.28	-2.47	1.45

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	560	541	491	720	1,135	1,760	1,522	1,545	1,491	1,503
Total Current Assets	450	402	270	522	851	1,295	857	884	732	817
Cash & Equivalents	94	161	100	113	434	714	308	133	214	174
Short-Term Investments	343	219	134	346	322	488	433	615	364	436
Accounts Receivable	-	0.00	5.17	13	33	23	28	40	73	122
Inventories, net	-	0.00	0.76	7.07	12	13	16	27	34	45
Prepaid Expenses	13	20	29	43	51	58	72	-	48	40
Other Current Assets	-	-	-	-	-	-	-	69	0.00	0.00
Plant, Property, & Equipment, net	7.37	17	22	20	44	74	141	260	291	266
Total Noncurrent Assets	102	122	199	177	240	391	525	402	468	420
Long-Term Investments	99	118	9.98	0.00	5.17	11	294	149	200	135
Goodwill	-	0.00	44	44	44	44	44	44	44	44
Intangible Assets	-	0.00	142	129	129	131	131	160	166	178
Other Noncurrent Operating Assets	0.60	1.84	3.41	3.51	62	205	55	48	58	63
Total Liabilities & Shareholders' Equity	560	541	491	720	1,135	1,760	1,522	1,545	1,491	1,503
Total Liabilities	28	67	107	111	482	605	600	1,193	1,216	1,241
Total Current Liabilities	28	60	71	75	103	190	181	261	280	344
Accounts Payable	2.94	5.36	8.89	12	13	13	17	43	42	39
Accrued Expenses	25	55	62	62	83	108	146	205	196	241
Other Current Liabilities	-	-	-	0.00	7.24	68	19	13	42	64
Total Noncurrent Liabilities	0.56	6.39	36	36	378	416	418	932	935	897
Noncurrent Deferred & Payable Income Tax Liabilities	-	0.00	31	31	33	33	33	32	30	30
Other Noncurrent Operating Liabilities	0.56	6.39	5.12	4.76	345	382	385	900	905	867
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	-	-	-	0.00	7.00
Total Equity & Noncontrolling Interests	531	474	383	609	654	1,154	923	352	275	255
Total Preferred & Common Equity	531	474	383	609	654	1,154	923	352	275	255
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	531	474	383	609	654	1,154	923	352	275	255
Common Stock	817	1,004	1,222	1,640	2,087	2,773	2,998	3,140	3,662	4,213
Retained Earnings	-285	-531	-833	-1,030	-1,433	-1,620	-2,074	-2,781	-3,388	-3,957
Treasury Stock	-	-	-	-	-	-	-	0.00	-0.43	-3.59
Accumulated Other Comprehensive Income / (Loss)	-0.87	0.91	-5.68	-0.63	-0.15	0.69	-1.40	-6.57	0.65	-0.64
Other Equity Adjustments	-	-	-	-	-	-	-	0.00	0.43	3.59

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	1,618	1,383	1,311	1,238	1,307	1,618	1,538	1,312
Total Current Assets	1,013	766	702	599	596	965	800	699
Cash & Equivalents	392	86	102	73	112	481	151	127
Short-Term Investments	497	544	450	370	300	283	471	367
Accounts Receivable	31	43	71	79	100	106	93	99
Inventories, net	22	27	28	32	36	40	43	46
Prepaid Expenses	71	67	51	46	0.00	-	-	60
Plant, Property, & Equipment, net	235	278	289	297	285	279	272	261
Total Noncurrent Assets	371	339	320	342	426	375	466	352
Long-Term Investments	121	90	72	86	157	111	203	69
Goodwill	44	44	44	44	44	44	44	44
Intangible Assets	158	159	158	157	165	166	165	177
Other Noncurrent Operating Assets	47	45	46	54	60	54	54	62
Total Liabilities & Shareholders' Equity	1,618	1,383	1,311	1,238	1,307	1,618	1,538	1,312
Total Liabilities	1,150	1,163	1,182	1,206	1,167	1,186	1,185	1,161
Total Current Liabilities	227	218	244	254	246	273	285	292
Accounts Payable	24	59	42	33	41	60	36	47
Accrued Expenses	189	144	168	179	149	154	185	173
Other Current Liabilities	15	15	35	42	55	59	64	71
Total Noncurrent Liabilities	922	945	938	952	921	913	900	869
Noncurrent Deferred & Payable Income Tax Liabilities	33	32	32	32	30	30	30	30
Other Noncurrent Operating Liabilities	889	913	906	921	891	883	869	839
Redeemable Noncontrolling Interest	-	-	-	-	-	-	7.00	7.00
Total Equity & Noncontrolling Interests	469	220	129	32	140	432	347	144
Total Preferred & Common Equity	469	220	129	32	140	432	347	144
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	469	220	129	32	140	432	347	144
Common Stock	3,108	3,169	3,237	3,298	3,699	4,123	4,169	4,253
Retained Earnings	-2,629	-2,945	-3,105	-3,264	-3,558	-3,690	-3,823	-4,108
Treasury Stock	-	-0.36	-0.38	-0.38	-3.33	-3.40	-3.56	-7.57
Accumulated Other Comprehensive Income / (Loss)	-10	-3.97	-3.10	-2.24	-0.43	-1.10	0.90	-0.34
Other Equity Adjustments	-	0.36	0.38	0.38	3.33	3.40	3.56	7.57

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	1,863.91%	1,871.48%	101.41%	161.32%	29.66%	3.39%	19.52%	29.01%
EBITDA Growth	-151.07%	-71.28%	-30.46%	39.74%	-122.74%	25.14%	-14.91%	-73.16%	11.62%	7.08%
EBIT Growth	-144.89%	-68.74%	-29.16%	35.91%	-105.65%	22.46%	-16.36%	-69.65%	12.44%	5.20%
NOPAT Growth	-160.20%	-67.87%	-32.63%	-12.90%	-14.22%	22.17%	-15.64%	-69.99%	12.28%	5.84%
Net Income Growth	-143.50%	-68.85%	-22.88%	34.60%	-103.80%	53.67%	-143.36%	-55.81%	14.25%	6.17%
EPS Growth	-76.00%	-56.82%	-14.65%	44.24%	-79.35%	56.88%	-118.24%	-51.04%	18.48%	23.76%
Operating Cash Flow Growth	-137.44%	-51.90%	-57.69%	-14.47%	-18.87%	61.72%	-156.16%	-12.33%	-24.80%	12.77%
Free Cash Flow Firm Growth	-170.01%	-54.59%	-158.66%	31.92%	84.80%	-581.75%	23.81%	89.93%	-1,951.27%	10.62%
Invested Capital Growth	-126.75%	-270.74%	603.14%	7.35%	-171.47%	45.93%	-93.35%	-388.14%	7.82%	3.78%
Revenue Q/Q Growth	0.00%	3.91%	1,186.70%	36.78%	22.91%	26.01%	-2.27%	5.81%	5.86%	7.17%
EBITDA Q/Q Growth	-37.13%	-7.42%	-8.81%	3.92%	-1.26%	0.44%	-1.48%	-7.66%	4.53%	-0.76%
EBIT Q/Q Growth	-36.06%	-6.86%	-8.96%	3.89%	-0.95%	-0.45%	-1.91%	-6.99%	4.28%	-1.10%
NOPAT Q/Q Growth	-36.14%	-6.16%	-8.68%	1.72%	-0.98%	-0.50%	-1.73%	-7.11%	3.98%	-0.04%
Net Income Q/Q Growth	-35.92%	-6.99%	-3.58%	-3.18%	-1.51%	27.23%	-27.69%	-4.33%	4.51%	-1.82%
EPS Q/Q Growth	-34.69%	-4.90%	-2.01%	2.70%	2.33%	30.07%	-28.35%	-4.01%	8.13%	1.56%
Operating Cash Flow Q/Q Growth	-35.89%	-4.71%	-15.54%	8.20%	-4.92%	6.76%	2.34%	-10.45%	1.34%	1.05%
Free Cash Flow Firm Q/Q Growth	-36.80%	-2.76%	-99.07%	40.85%	87.90%	-237.43%	46.31%	-192.68%	4.06%	1.62%
Invested Capital Q/Q Growth	-23.69%	-36.50%	524.54%	-6.46%	-152.00%	74.78%	-18.73%	-0.56%	-1.05%	-2.52%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	99.96%	97.77%	91.31%	97.74%	95.44%	92.21%	89.59%	86.30%
EBITDA Margin	0.00%	-181,475.19%	-12,055.17%	-368.47%	-407.50%	-116.74%	-103.46%	-173.28%	-128.12%	-92.29%
Operating Margin	0.00%	-186,471.43%	-12,593.49%	-721.18%	-408.98%	-121.80%	-108.63%	-178.60%	-131.08%	-95.67%
EBIT Margin	0.00%	-187,690.23%	-12,343.49%	-401.28%	-409.74%	-121.58%	-109.11%	-179.03%	-131.16%	-96.38%
Profit (Net Income) Margin	0.00%	-184,867.67%	-11,567.34%	-383.75%	-388.31%	-68.84%	-129.20%	-194.71%	-139.70%	-101.60%
Tax Burden Percent	100.00%	100.01%	94.91%	100.26%	100.82%	100.65%	100.23%	100.81%	99.70%	100.28%
Interest Burden Percent	98.43%	98.48%	98.74%	95.38%	94.00%	56.25%	118.14%	107.88%	106.83%	105.12%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-413.53%	-180.41%	-1,395.24%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-394.26%	-198.12%	-1,377.90%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	343.06%	140.58%	1,331.45%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-40.67%	-48.93%	-70.48%	-39.83%	-63.79%	-20.64%	-43.72%	-110.96%	-193.23%	-211.71%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-285.55%	-187.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-45.38%	-62.52%	-34.15%	-45.82%	-22.76%	-23.37%	-42.41%	-37.51%	-36.06%
Return on Assets (ROA)	0.00%	-44.70%	-58.59%	-32.65%	-43.42%	-12.89%	-27.67%	-46.12%	-39.96%	-38.02%
Return on Common Equity (ROCE)	-40.67%	-48.93%	-70.48%	-39.83%	-63.79%	-20.64%	-43.72%	-110.96%	-193.23%	-208.95%
Return on Equity Simple (ROE_SIMPLE)	-27.42%	-51.88%	-78.79%	-32.45%	-61.60%	-16.16%	-49.21%	-200.69%	-220.26%	-222.95%
Net Operating Profit after Tax (NOPAT)	-103	-174	-230	-260	-297	-231	-267	-454	-398	-375
NOPAT Margin	0.00%	-130,530.00%	-8,815.44%	-504.83%	-286.29%	-85.26%	-76.04%	-125.02%	-91.76%	-66.97%
Net Nonoperating Expense Percent (NNEP)	-11.61%	-13.90%	-19.27%	17.71%	-17.34%	4.51%	-16.63%	-26.23%	-24.88%	-25.49%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-128.87%	-144.67%	-146.96%
Cost of Revenue to Revenue	0.00%	0.00%	0.04%	2.23%	8.69%	2.26%	4.56%	7.79%	10.41%	13.70%
SG&A Expenses to Revenue	0.00%	48,824.06%	3,825.00%	248.03%	155.74%	67.50%	62.60%	76.55%	71.34%	57.41%
R&D to Revenue	0.00%	137,747.37%	8,868.45%	570.93%	344.56%	152.04%	141.48%	194.26%	149.33%	124.57%
Operating Expenses to Revenue	0.00%	186,571.43%	12,693.45%	818.96%	500.30%	219.54%	204.08%	270.81%	220.67%	181.97%
Earnings before Interest and Taxes (EBIT)	-148	-250	-322	-207	-425	-330	-383	-650	-570	-540
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-141	-241	-315	-190	-423	-316	-364	-630	-556	-517
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.20	6.06	5.15	3.61	3.77	7.32	6.21	9.21	14.26	15.22
Price to Tangible Book Value (P/TBV)	8.20	6.06	10.00	5.05	5.14	8.63	7.67	21.95	60.66	119.25
Price to Revenue (P/Rev)	0.00	21,600.43	756.23	42.71	23.79	31.18	16.31	8.94	9.04	6.93
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	12.45	11.66	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	17,844.62	662.64	33.78	16.46	26.71	13.37	6.47	7.25	5.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.03	-0.87	-0.71	-0.97	-1.09	-1.08	-1.51	-2.67	-2.83
Leverage Ratio	1.06	1.09	1.20	1.22	1.47	1.60	1.58	2.41	4.84	5.57
Compound Leverage Factor	1.04	1.08	1.19	1.16	1.38	0.90	1.87	2.60	5.17	5.85
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.67%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	97.33%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	91.10	23.72	6.99	9.79	0.95	7.38	3.76	-1.56	-1.85	-2.24
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.30%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	16.13	6.67	3.80	6.99	8.24	6.83	4.72	3.38	2.61	2.37
Quick Ratio	15.65	6.31	3.37	6.32	7.63	6.46	4.24	3.02	2.32	2.13
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-99	-153	-397	-270	-41	-280	-213	-21	-441	-394
Operating Cash Flow to CapEx	-2,138.79%	-1,580.05%	-9,088.54%	-7,128.70%	-1,390.88%	-301.15%	-463.38%	-327.64%	-1,072.60%	-5,529.14%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-36.19	-8.41	-7.25	-0.50	-6.68	-6.25
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	-304.30	-3.97	-11.51	-8.84	-7.19	-6.57
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-326.18	-5.29	-14.00	-11.54	-7.86	-6.69
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.01	0.09	0.11	0.19	0.21	0.24	0.29	0.37
Accounts Receivable Turnover	0.00	0.00	0.00	5.75	4.55	9.69	13.64	10.55	7.63	5.74
Inventory Turnover	0.00	0.00	0.00	0.29	0.97	0.50	1.09	1.32	1.49	1.94
Fixed Asset Turnover	0.00	0.01	0.13	2.46	3.22	4.60	3.27	1.81	1.58	2.01
Accounts Payable Turnover	0.00	0.00	0.00	0.11	0.72	0.48	1.07	0.94	1.06	1.90
Days Sales Outstanding (DSO)	0.00	0.00	0.00	63.48	80.21	37.67	26.76	34.60	47.84	63.59
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	1,245.65	377.05	732.32	333.80	277.08	245.18	187.85
Days Payable Outstanding (DPO)	0.00	0.00	2,600,625.00	3,369.88	509.45	768.05	342.71	389.31	344.69	192.35
Cash Conversion Cycle (CCC)	0.00	0.00	-2,600,625.00	-2,060.75	-52.19	1.93	17.84	-77.63	-51.68	59.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-7.45	-28	139	149	-107	-58	-111	-544	-502	-483
Invested Capital Turnover	0.00	-0.01	0.05	0.36	4.87	-3.30	-4.15	-1.11	-0.83	-1.14
Increase / (Decrease) in Invested Capital	-4.17	-20	167	10	-256	49	-54	-433	43	19
Enterprise Value (EV)	3,820	2,373	1,731	1,739	1,707	7,238	4,698	2,351	3,150	3,147
Market Capitalization	4,356	2,873	1,975	2,199	2,467	8,450	5,732	3,248	3,927	3,885
Book Value per Share	$13.68	$11.60	$9.00	$12.04	$11.32	$18.91	$13.53	$5.03	$3.35	$2.76
Tangible Book Value per Share	$13.68	$11.60	$4.64	$8.61	$8.31	$16.04	$10.96	$2.11	$0.79	$0.35
Total Capital	531	474	383	609	654	1,154	923	352	275	262
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-536	-500	-244	-460	-760	-1,212	-1,034	-897	-777	-745
Capital Expenditures (CapEx)	4.96	10	2.79	4.08	25	44	73	116	44	7.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-40	-36	-12	-7.51	-96	-65	-125	-125	-137
Debt-free Net Working Capital (DFNWC)	422	341	199	448	748	1,106	675	623	452	473
Net Working Capital (NWC)	422	341	199	448	748	1,106	675	623	452	473
Net Nonoperating Expense (NNE)	42	72	72	-62	106	-45	187	253	208	194
Net Nonoperating Obligations (NNO)	-539	-502	-244	-460	-760	-1,212	-1,034	-897	-777	-745
Total Depreciation and Amortization (D&A)	7.02	8.27	7.53	17	2.33	13	20	21	13	23
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-30,167.67%	-1,375.34%	-23.42%	-7.24%	-35.36%	-18.49%	-34.42%	-28.89%	-24.46%
Debt-free Net Working Capital to Revenue	0.00%	256,718.80%	7,602.18%	869.30%	720.94%	407.96%	192.15%	171.38%	104.03%	84.42%
Net Working Capital to Revenue	0.00%	256,718.80%	7,602.18%	869.30%	720.94%	407.96%	192.15%	171.38%	104.03%	84.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.96)	($6.21)	($7.12)	($3.97)	($7.12)	($3.07)	($6.70)	($10.12)	($8.25)	($6.29)
Adjusted Weighted Average Basic Shares Outstanding	38.98M	41.73M	49.61M	51.28M	57.89M	66.95M	69.38M	69.91M	73.54M	90.54M
Adjusted Diluted Earnings per Share	($3.96)	($6.21)	($7.12)	($3.97)	($7.12)	($3.07)	($6.70)	($10.12)	($8.25)	($6.29)
Adjusted Weighted Average Diluted Shares Outstanding	38.98M	41.73M	49.61M	51.28M	57.89M	66.95M	69.38M	69.91M	73.54M	90.54M
Adjusted Basic & Diluted Earnings per Share	($3.96)	($6.21)	($7.12)	($3.97)	($7.12)	($3.07)	($6.70)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.78M	39.59M	42.45M	49.78M	56.58M	60.85M	67.80M	70.22M	82.34M	92.50M
Normalized Net Operating Profit after Tax (NOPAT)	-103	-174	-230	-260	-297	-231	-267	-454	-398	-375
Normalized NOPAT Margin	0.00%	-130,530.00%	-8,815.44%	-504.83%	-286.29%	-85.26%	-76.04%	-125.02%	-91.76%	-66.97%
Pre Tax Income Margin	0.00%	-184,841.35%	-12,187.52%	-382.75%	-385.14%	-68.39%	-128.91%	-193.14%	-140.12%	-101.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	-374.41	-9.90	-13.03	-15.12	-8.63	-8.56
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-261.60	-6.94	-9.08	-10.56	-6.04	-5.95
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-396.29	-11.22	-15.52	-17.82	-9.30	-8.68
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-283.48	-8.26	-11.57	-13.26	-6.71	-6.07
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.09%	23.93%	25.72%	21.23%	8.10%	23.27%	8.30%	35.75%	42.27%	29.42%	27.99%
EBITDA Growth	-159.31%	-46.04%	-16.26%	-8.24%	35.93%	18.58%	-6.80%	24.04%	12.75%	-3.35%	16.69%
EBIT Growth	-150.62%	-41.25%	-12.80%	-5.21%	35.54%	17.49%	-8.55%	21.18%	11.58%	-4.90%	14.88%
NOPAT Growth	-150.55%	-41.99%	-12.79%	-4.49%	35.53%	16.19%	-7.30%	21.35%	9.04%	-0.19%	13.55%
Net Income Growth	-235.77%	-23.99%	-7.65%	-1.05%	34.87%	18.86%	-4.09%	17.66%	16.37%	-8.28%	11.49%
EPS Growth	-224.07%	-21.91%	-6.39%	0.44%	36.29%	33.64%	12.88%	32.44%	37.22%	6.94%	22.66%
Operating Cash Flow Growth	-59.84%	-66.24%	-33.48%	-50.36%	-23.63%	7.13%	-21.59%	33.74%	43.16%	5.25%	12.72%
Free Cash Flow Firm Growth	246.61%	1,941.31%	282.05%	305.87%	-150.48%	-138.69%	-149.90%	-136.94%	19.32%	18.30%	37.47%
Invested Capital Growth	-476.35%	-388.14%	-2,765.65%	-1,665.62%	8.26%	7.82%	14.20%	10.65%	5.16%	3.78%	3.88%
Revenue Q/Q Growth	1.52%	13.94%	-2.76%	7.77%	-9.47%	29.92%	-14.57%	35.09%	-5.12%	18.20%	-15.52%
EBITDA Q/Q Growth	-61.48%	35.54%	-6.62%	2.48%	4.41%	18.08%	-39.86%	30.64%	-9.79%	2.97%	-12.74%
EBIT Q/Q Growth	-58.69%	35.69%	-5.74%	2.50%	2.77%	17.69%	-39.12%	29.21%	-9.07%	2.35%	-12.88%
NOPAT Q/Q Growth	-58.95%	35.30%	-5.82%	3.99%	1.93%	15.88%	-35.48%	29.63%	-13.43%	7.36%	-16.90%
Net Income Q/Q Growth	-54.97%	38.05%	-8.00%	2.53%	0.11%	22.84%	-38.55%	22.90%	-1.46%	0.10%	-13.27%
EPS Q/Q Growth	-54.87%	38.00%	-7.37%	3.43%	0.89%	35.43%	-40.97%	25.12%	7.89%	4.29%	-17.16%
Operating Cash Flow Q/Q Growth	-23.41%	5.25%	-73.64%	25.95%	-1.47%	28.82%	-127.32%	59.65%	12.95%	-18.67%	-109.39%
Free Cash Flow Firm Q/Q Growth	264.24%	14.17%	13.05%	-2.89%	-140.27%	12.51%	-45.83%	28.11%	12.04%	11.40%	-11.61%
Invested Capital Q/Q Growth	-1,831.25%	-0.56%	8.26%	0.90%	-0.35%	-1.05%	14.61%	-3.19%	-6.51%	-2.52%	14.70%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.48%	94.85%	87.80%	90.85%	88.79%	90.54%	83.89%	85.53%	84.93%	89.75%	79.42%
EBITDA Margin	-243.11%	-137.54%	-150.81%	-136.47%	-144.09%	-90.85%	-148.73%	-76.36%	-88.37%	-72.55%	-96.81%
Operating Margin	-248.14%	-140.91%	-153.34%	-136.61%	-147.98%	-95.81%	-151.93%	-79.14%	-94.62%	-74.16%	-102.62%
EBIT Margin	-249.35%	-140.74%	-153.04%	-138.44%	-148.69%	-94.20%	-153.40%	-80.39%	-92.41%	-76.35%	-102.02%
Profit (Net Income) Margin	-270.23%	-146.91%	-163.16%	-147.57%	-162.82%	-96.70%	-156.83%	-89.51%	-95.71%	-80.90%	-108.46%
Tax Burden Percent	102.63%	99.05%	100.30%	100.46%	100.41%	97.08%	100.27%	100.66%	100.23%	99.99%	100.87%
Interest Burden Percent	105.59%	105.39%	106.29%	106.10%	109.06%	105.74%	101.96%	110.62%	103.34%	105.97%	105.40%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-96.69%	-110.96%	-141.42%	-178.60%	-253.84%	-193.23%	-340.05%	-208.43%	-289.98%	-211.71%	-377.06%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-55.18%	-33.34%	-42.46%	-42.38%	-42.70%	-26.94%	-50.47%	-26.41%	-34.80%	-28.57%	-46.02%
Return on Assets (ROA)	-59.80%	-34.80%	-45.27%	-45.17%	-46.76%	-27.66%	-51.60%	-29.41%	-36.04%	-30.27%	-48.93%
Return on Common Equity (ROCE)	-96.69%	-110.96%	-141.42%	-178.60%	-253.84%	-193.23%	-340.05%	-208.43%	-284.71%	-208.95%	-368.00%
Return on Equity Simple (ROE_SIMPLE)	-144.63%	0.00%	-326.14%	-558.58%	-2,003.16%	0.00%	-437.28%	-135.31%	-161.17%	0.00%	-381.00%
Net Operating Profit after Tax (NOPAT)	-158	-102	-108	-104	-102	-85	-116	-81	-92	-86	-100
NOPAT Margin	-173.69%	-98.64%	-107.34%	-95.62%	-103.59%	-67.06%	-106.35%	-55.40%	-66.23%	-51.91%	-71.83%
Net Nonoperating Expense Percent (NNEP)	-8.59%	-5.17%	-7.32%	-8.46%	-7.55%	-4.51%	-8.53%	-6.69%	-6.08%	-6.28%	-9.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-28.92%	-	-	-	-31.02%	-	-	-	-33.53%	-69.37%
Cost of Revenue to Revenue	9.52%	5.15%	12.20%	9.15%	11.21%	9.46%	16.11%	14.47%	15.07%	10.25%	20.58%
SG&A Expenses to Revenue	77.00%	70.49%	76.27%	75.16%	76.41%	60.31%	71.82%	54.82%	57.60%	50.03%	63.03%
R&D to Revenue	261.62%	165.27%	164.88%	152.29%	160.37%	126.03%	164.00%	109.85%	121.95%	113.88%	119.01%
Operating Expenses to Revenue	338.62%	235.76%	241.15%	227.45%	236.77%	186.35%	235.82%	164.67%	179.55%	163.92%	182.04%
Earnings before Interest and Taxes (EBIT)	-226	-145	-154	-150	-146	-120	-167	-118	-129	-126	-142
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-221	-142	-152	-148	-141	-116	-162	-112	-123	-120	-135
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.19	9.21	12.77	25.32	80.36	14.26	27.33	7.90	14.76	15.22	23.22
Price to Tangible Book Value (P/TBV)	10.90	21.95	166.57	0.00	0.00	60.66	0.00	15.41	37.24	119.25	0.00
Price to Revenue (P/Rev)	8.45	8.94	7.33	8.11	6.21	9.04	8.66	7.10	9.79	6.93	5.67
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.50	6.47	5.46	6.56	4.93	7.25	7.38	5.28	8.23	5.62	4.73
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	81.49	0.00	136.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.45	-1.51	-1.51	-1.65	-3.07	-2.67	-3.57	-2.67	-3.51	-2.83	-3.88
Leverage Ratio	2.21	2.41	2.72	3.26	5.71	4.84	7.46	5.22	7.20	5.57	8.98
Compound Leverage Factor	2.34	2.54	2.89	3.46	6.22	5.11	7.60	5.77	7.44	5.90	9.47
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.98%	2.67%	4.63%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	98.02%	97.33%	95.37%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.43	-0.48	-1.14	-1.31	-2.15	-0.85	-1.60	-0.89	-0.42	-1.33	-2.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.82%	1.30%	2.40%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.45	3.38	3.51	2.87	2.36	2.61	2.43	3.54	2.81	2.37	2.40
Quick Ratio	4.05	3.02	3.08	2.55	2.05	2.32	2.09	3.19	2.51	2.13	2.03
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	290	331	374	363	-146	-128	-187	-134	-118	-105	-117
Operating Cash Flow to CapEx	-366.06%	-334.97%	-626.62%	-833.41%	-3,190.09%	-5,244.00%	-5,939.80%	-3,830.91%	-4,143.17%	-12,156.42%	-12,573.64%
Free Cash Flow to Firm to Interest Expense	19.98	20.84	23.92	23.62	-8.28	-7.39	-11.78	-8.41	-7.51	-6.74	-8.14
Operating Cash Flow to Interest Expense	-6.57	-5.69	-10.03	-7.56	-6.67	-4.84	-12.04	-4.82	-4.26	-5.12	-11.61
Operating Cash Flow Less CapEx to Interest Expense	-8.37	-7.39	-11.63	-8.46	-6.88	-4.93	-12.24	-4.95	-4.37	-5.16	-11.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.22	0.24	0.28	0.31	0.29	0.29	0.33	0.33	0.38	0.37	0.45
Accounts Receivable Turnover	12.14	10.55	10.76	7.48	7.43	7.63	6.18	5.45	6.06	5.74	5.93
Inventory Turnover	1.43	1.32	1.55	1.46	1.43	1.49	1.61	1.81	1.91	1.94	2.14
Fixed Asset Turnover	1.94	1.81	1.69	1.62	1.54	1.58	1.57	1.70	1.84	2.01	2.16
Accounts Payable Turnover	1.36	0.94	0.83	0.95	1.35	1.06	1.01	1.21	2.07	1.90	1.99
Days Sales Outstanding (DSO)	30.05	34.60	33.92	48.80	49.13	47.84	59.07	66.93	60.25	63.59	61.51
Days Inventory Outstanding (DIO)	254.99	277.08	235.16	249.26	254.47	245.18	226.02	201.80	190.75	187.85	170.20
Days Payable Outstanding (DPO)	269.23	389.31	437.58	385.64	269.83	344.69	361.32	300.74	176.06	192.35	183.67
Cash Conversion Cycle (CCC)	15.82	-77.63	-168.50	-87.58	33.77	-51.68	-76.24	-32.01	74.94	59.08	48.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-541	-544	-499	-495	-496	-502	-428	-442	-471	-483	-412
Invested Capital Turnover	-1.08	-1.11	-1.49	-1.54	-0.79	-0.83	-0.95	-1.03	-1.08	-1.14	-1.41
Increase / (Decrease) in Invested Capital	-447	-433	-482	-467	45	43	71	53	26	19	17
Enterprise Value (EV)	1,890	2,351	2,096	2,643	2,020	3,150	3,265	2,542	4,302	3,147	2,793
Market Capitalization	2,900	3,248	2,816	3,267	2,549	3,927	3,834	3,417	5,120	3,885	3,349
Book Value per Share	$6.69	$5.03	$3.14	$1.82	$0.44	$3.35	$1.66	$5.20	$3.76	$2.76	$1.56
Tangible Book Value per Share	$3.80	$2.11	$0.24	($1.04)	($2.38)	$0.79	($0.82)	$2.67	$1.49	$0.35	($0.83)
Total Capital	469	352	220	129	32	275	140	432	354	262	151
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,010	-897	-720	-624	-528	-777	-569	-874	-825	-745	-563
Capital Expenditures (CapEx)	26	27	25	14	3.70	1.60	3.21	2.01	1.62	0.65	1.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-103	-125	-81	-94	-97	-125	-62	-72	-107	-137	-87
Debt-free Net Working Capital (DFNWC)	785	623	548	458	345	452	350	692	515	473	407
Net Working Capital (NWC)	785	623	548	458	345	452	350	692	515	473	407
Net Nonoperating Expense (NNE)	88	50	56	56	58	38	55	50	41	48	51
Net Nonoperating Obligations (NNO)	-1,010	-897	-720	-624	-528	-777	-569	-874	-825	-745	-563
Total Depreciation and Amortization (D&A)	5.66	3.31	2.24	2.14	4.51	4.27	5.09	5.92	5.64	6.27	7.26
Debt-free, Cash-free Net Working Capital to Revenue	-30.10%	-34.42%	-21.15%	-23.39%	-23.62%	-28.89%	-13.94%	-14.97%	-20.47%	-24.46%	-14.72%
Debt-free Net Working Capital to Revenue	228.71%	171.38%	142.79%	113.63%	84.16%	104.03%	79.17%	143.73%	98.44%	84.42%	68.99%
Net Working Capital to Revenue	228.71%	171.38%	142.79%	113.63%	84.16%	104.03%	79.17%	143.73%	98.44%	84.42%	68.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.50)	($2.17)	($2.33)	($2.25)	($2.23)	($1.44)	($2.03)	($1.52)	($1.40)	($1.34)	($1.57)
Adjusted Weighted Average Basic Shares Outstanding	70.05M	69.91M	70.37M	70.90M	71.66M	73.54M	84.29M	86.58M	95.49M	90.54M	96.29M
Adjusted Diluted Earnings per Share	($3.50)	($2.17)	($2.33)	($2.25)	($2.23)	($1.44)	($2.03)	($1.52)	($1.40)	($1.34)	($1.57)
Adjusted Weighted Average Diluted Shares Outstanding	70.05M	69.91M	70.37M	70.90M	71.66M	73.54M	84.29M	86.58M	95.49M	90.54M	96.29M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	70.11M	70.22M	70.81M	71.49M	82.11M	82.34M	83.13M	92.17M	92.34M	92.50M	94.54M
Normalized Net Operating Profit after Tax (NOPAT)	-158	-102	-108	-104	-102	-85	-116	-81	-92	-86	-100
Normalized NOPAT Margin	-173.69%	-98.64%	-107.34%	-95.62%	-103.59%	-67.06%	-106.35%	-55.40%	-66.23%	-51.91%	-71.83%
Pre Tax Income Margin	-263.30%	-148.32%	-162.67%	-146.89%	-162.16%	-99.61%	-156.41%	-88.92%	-95.50%	-80.91%	-107.52%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-15.59	-9.16	-9.84	-9.75	-8.25	-6.93	-10.54	-7.41	-8.20	-8.11	-9.91
NOPAT to Interest Expense	-10.86	-6.42	-6.90	-6.74	-5.75	-4.93	-7.30	-5.10	-5.88	-5.51	-6.98
EBIT Less CapEx to Interest Expense	-17.39	-10.86	-11.44	-10.66	-8.46	-7.02	-10.74	-7.53	-8.31	-8.15	-10.00
NOPAT Less CapEx to Interest Expense	-12.66	-8.12	-8.50	-7.64	-5.96	-5.02	-7.51	-5.23	-5.98	-5.56	-7.07
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Over the past four Q1s, Ultragenyx has steadily grown revenue, improved its cost structure and reduced its cash burn, but it remains unprofitable and heavily invests in R&D.

Q1 ’25 revenue jumped 27.99% year-over-year to $139.3 M, the strongest top-line growth in this four-year span.
Net loss narrowed to $151.1 M (EPS –1.57) vs. –$170.7 M (–2.03) in Q1 ’24, reflecting improving operating performance.
Operating cash flow burn eased to –$166.5 M (vs. –$190.7 M in Q1 ’24) and free cash flow loss improved to –$116.7 M, boosting cash runway.
R&D and SG&A intensity declined: R&D/revenue fell to 119% (from 164%) and SG&A/revenue to 63% (from 72%), signaling tighter cost control.
Liquidity remains ample with $127 M cash, $367 M short-term investments and a 2.40 current ratio; the company is debt-free.
Gross margin eased to 79.4% (vs. 83.9% a year ago) but remains above industry averages.
Valuation multiples have declined: price/revenue is 5.67× vs. 8.66× a year ago, making shares more attractive.
The Altman Z-Score remains negative at –2.19, reflecting biotech sector volatility and ongoing cash burn.
Ultragenyx remains unprofitable with operating and net losses exceeding $150 M, driven by heavy pipeline investment.
Cash conversion cycle remains elongated (~48 days) and high cash burn continues to pressure balance sheet stability.

06/20/25 06:17 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Ultragenyx Pharmaceutical's Financials

When does Ultragenyx Pharmaceutical's fiscal year end?

According to the most recent income statement we have on file, Ultragenyx Pharmaceutical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ultragenyx Pharmaceutical's net income changed over the last 9 years?

Ultragenyx Pharmaceutical's net income appears to be on an upward trend, with a most recent value of -$569.18 million in 2024, rising from -$145.62 million in 2015. The previous period was -$606.64 million in 2023. See Ultragenyx Pharmaceutical's forecast for analyst expectations on what’s next for the company.

What is Ultragenyx Pharmaceutical's operating income?

Ultragenyx Pharmaceutical's total operating income in 2024 was -$535.97 million, based on the following breakdown:

Total Gross Profit: $483.50 million
Total Operating Expenses: $1.02 billion

How has Ultragenyx Pharmaceutical's revenue changed over the last 9 years?

Over the last 9 years, Ultragenyx Pharmaceutical's total revenue changed from $0.00 in 2015 to $560.23 million in 2024, a change of 56,023,000,000.0%.

How much debt does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical's total liabilities were at $1.24 billion at the end of 2024, a 2.1% increase from 2023, and a 4,258.2% increase since 2015.

How much cash does Ultragenyx Pharmaceutical have?

In the past 9 years, Ultragenyx Pharmaceutical's cash and equivalents has ranged from $93.57 million in 2015 to $713.53 million in 2020, and is currently $173.73 million as of their latest financial filing in 2024.

How has Ultragenyx Pharmaceutical's book value per share changed over the last 9 years?

Over the last 9 years, Ultragenyx Pharmaceutical's book value per share changed from 13.68 in 2015 to 2.76 in 2024, a change of -79.8%.

Related Companies

This page (NASDAQ:RARE) was last updated on 6/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Financials

Key Financial Trends

Frequently Asked Questions About Ultragenyx Pharmaceutical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Financials

Annual Income Statements for Ultragenyx Pharmaceutical

Quarterly Income Statements for Ultragenyx Pharmaceutical

Annual Cash Flow Statements for Ultragenyx Pharmaceutical

Quarterly Cash Flow Statements for Ultragenyx Pharmaceutical

Annual Balance Sheets for Ultragenyx Pharmaceutical

Quarterly Balance Sheets for Ultragenyx Pharmaceutical

Annual Metrics And Ratios for Ultragenyx Pharmaceutical

Quarterly Metrics And Ratios for Ultragenyx Pharmaceutical

Key Financial Trends

Frequently Asked Questions About Ultragenyx Pharmaceutical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools